Search - tctmd.com

Displaying 181 - 193 of 193

Sort: Relevancy | Date

News Conference News TCT 2012

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

October 23, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 22, 2012

Presentation TCT 2012

Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients with Chronic Kidney Disease: A Report From the National Heart, Lung, and Blood...

Presenter: Joseph Kim, Helen Vlachos, Suresh R. Mulukutla, Catalin Toma, Joon S. Lee, David O. Williams, Sheryl F. Kelsey, Kevin E. Kip, Oscar C. Marroquin

January 03, 2012

Presentation TCT 2012

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

Presenter: Miltiadis Papalexandris, Hubertus Degen, Carsten Stoepel, Thomas Lickfeld, Thorsten Schneider, Carlos Freitas, Michael Haude

January 03, 2012

Presentation TCT 2012

”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug Eluting Stents.”

Presenter: Andrzej Drewnicki, Maciej Lesiak, Malgorzata Pyda, Marek Grygier, Wlodzimierz Skorupski, Aleksander Araszkiewicz, Przemyslaw Mitkowski, Stefan Grajek

January 03, 2012

News Conference News

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

November 27, 2011

News Conference News

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

November 10, 2011

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

News Conference News

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

November 08, 2011

News Conference News

Low Event Rates with EES Sustained at 2 Years

November 08, 2011

News Conference News

ZES, EES Noninferior to PES

November 07, 2011

News Conference News

SAT-TAVI: Data Support TAVR Without Dual Antiplatelet Therapy

November 07, 2011

News Conference News

GHOST: Accurate Medical History May Predict DAPT Adherence in PCI for STEMI

November 06, 2011

Advertisement

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients with Chronic Kidney Disease: A Report From the National Heart, Lung, and Blood...

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug Eluting Stents.”

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

Low Event Rates with EES Sustained at 2 Years

ZES, EES Noninferior to PES

SAT-TAVI: Data Support TAVR Without Dual Antiplatelet Therapy

GHOST: Accurate Medical History May Predict DAPT Adherence in PCI for STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content